BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hori T, Uemoto S, Walden LB, Chen F, Baine AM, Hata T, Kogure T, Nguyen JH. Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: A pilot study in mice. Hepatol Res 2014;44:651-62. [PMID: 23672352 DOI: 10.1111/hepr.12161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Duarte S, Baber J, Fujii T, Coito AJ. Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol 2015;44-46:147-56. [PMID: 25599939 DOI: 10.1016/j.matbio.2015.01.004] [Cited by in Crossref: 215] [Cited by in F6Publishing: 201] [Article Influence: 30.7] [Reference Citation Analysis]
2 Dawood RM, El-meguid MA, Salum GM, El Awady MK. Key Players of Hepatic Fibrosis. Journal of Interferon & Cytokine Research 2020;40:472-89. [DOI: 10.1089/jir.2020.0059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Ogawa M, Matsuoka S, Karp SJ, Moriyama M. Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. Int J Mol Sci 2020;21:E4906. [PMID: 32664553 DOI: 10.3390/ijms21144906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Roeb E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 2018;68-69:463-473. [PMID: 29289644 DOI: 10.1016/j.matbio.2017.12.012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
5 Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L, Sun X. Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis. Bioorg Med Chem Lett 2016;26:2174-8. [PMID: 27038494 DOI: 10.1016/j.bmcl.2016.03.064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
6 Geervliet E, Bansal R. Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells. 2020;9. [PMID: 32414178 DOI: 10.3390/cells9051212] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
7 Zhong Y, Lu YT, Sun Y, Shi ZH, Li NG, Tang YP, Duan JA. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opin Drug Discov 2018;13:75-87. [PMID: 29088927 DOI: 10.1080/17460441.2018.1398732] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]